Results from this study suggest that the expression of PD-L1 by tumor-infiltrating lymphocytes (TIL) may predict the response to ICI therapy in breast cancer, as patients with TILs expressing PD-L1 showed an increased ORR in the overall population (16.7% vs. 1.6%), an effect that was remarkable in the TNBC subgroup, with an ORR of 22.2% vs. 2.6% (179). This evidence concerns the gene CD274 and breast cancer.